Shares of Morepen Laboratories fell 4% on August 6 after the company reported a sharp decline in its financial performance for the first quarter of FY26. The stock opened at ₹57.20 but slipped to a low of ₹51.66 during the day, reacting to the disappointing earnings.
In Q1, Morepen Labs reported a 68.5% year-on-year (YoY) drop in net profit, which came in at ₹11.4 crore compared to ₹36.2 crore in the same quarter last year.
Revenue for the quarter stood at ₹425 crore, down 6.6% from ₹455 crore a year ago. The decline in topline was mirrored by a 53.4% fall in EBITDA, which dropped to ₹24 crore from ₹51.5 crore YoY. EBITDA margin also halved, narrowing sharply to 5.7% from 11.3% last year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
